Biotest

Biotest ROE

Delisted

The Return on Equity (ROE) of Biotest (BIO.DE) as of Nov 19, 2026 is 4.97 %. In the previous year, Return on Equity (ROE) was 25.46 % — a change of -80.46% (lower).

ROE

4.97 %

YoY

-80.46%

Last updated:

In 2024, Biotest's return on equity (ROE) was 4.97 %, a -80.46% increase from the 25.46 % ROE in the previous year.

The Biotest ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2017
-1.01 EUR
Jan 1, 2018
36.71 EUR
Jan 1, 2019
-0.99 EUR
Jan 1, 2020
-7.11 EUR
Jan 1, 2021
-16.67 EUR
Jan 1, 2022
-8.54 EUR
Jan 1, 2023
25.46 EUR
Jan 1, 2024
4.97 EUR
The Biotest ROE history
YEARROEYoY
4.97 %-80.46%
25.46 %-398.00%
-8.54 %-48.75%
-16.67 %+134.39%
-7.11 %+621.49%
-0.99 %-102.68%
36.71 %-3,745.54%
-1.01 %-92.07%
-12.70 %-36.52%
-20.01 %-600.47%
4.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biotest Stock analysis

What does Biotest do? Biotest AG is an innovative and successful company that operates in the fields of medicine, pharmacy, and biotechnology. It was founded in 1946 by Dr. Carl Adolf Vorherr in Dreieich near Frankfurt am Main. The company's original focus was on the development, production, and distribution of blood plasma products. In the 1950s, Biotest expanded into the field of transfusion medicine and began to clinically examine and process blood from donors. It became a leading manufacturer of concentrate preparations for the treatment of immune deficiencies and blood coagulation disorders in the 1960s. In the 1970s, the company became a leading manufacturer of monoclonal and polyclonal antibodies and an important research and development facility for biotechnological applications. Biotest today is divided into five research and business areas: Hematology & Immunology, Clinical Immunology, Biotherapeutics, Dermatology, and Research and Development. The company is globally present with locations in Europe, North America, Asia, and South America. It employs over 2,500 people and its products are available in more than 90 countries. It invests in research and development to stay at the forefront of technology and improve global health. Biotest is one of the most popular companies on Eulerpool.

ROE Details

Decoding Biotest's Return on Equity (ROE)

Biotest's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Biotest's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Biotest's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Biotest’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Biotest stock

Return on Equity (ROE) of Biotest is 4.97 % in 2024.

Return on Equity (ROE) of Biotest changed from 25.46 % to 4.97 %, representing a -80.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Biotest since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Biotest with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Biotest

All Key Metrics — Biotest